G
Graham Jackson
Researcher at University of Newcastle
Publications - 454
Citations - 19176
Graham Jackson is an academic researcher from University of Newcastle. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 65, co-authored 426 publications receiving 16880 citations. Previous affiliations of Graham Jackson include Freeman Hospital & London Bridge Hospital.
Papers
More filters
Journal ArticleDOI
Summary of the recommendations on sexual dysfunctions in men
Francesco Montorsi,Ganesan Adaikan,Edgardo Becher,François Giuliano,Saad Khoury,Tom F. Lue,Ira D. Sharlip,Stanley E. Althof,Karl Eric Andersson,Gerald B. Brock,Gregory A. Broderick,Arthur L. Burnett,Jacques Buvat,John Dean,Craig F. Donatucci,Ian Eardley,Kerstin S. Fugl-Meyer,Irwin Goldstein,Geoff Hackett,Dimitris Hatzichristou,Wayne J.G. Hellstrom,Luca Incrocci,Graham Jackson,Ates Kadioglu,Laurence A. Levine,Ronald W. Lewis,Mario Maggi,Marita P. McCabe,Chris McMahon,Drogo K. Montague,Piero Montorsi,John P. Mulhall,James G. Pfaus,Hartmut Porst,David Ralph,Raymond C. Rosen,David L. Rowland,Hossein Sadeghi-Nejad,Ridwan Shabsigh,Christian G. Stief,Yoram Vardi,Kim Wallen,Marlene Wasserman +42 more
TL;DR: Specific evaluation, treatment guidelines, and algorithms were developed for every sexual dysfunction in men, including erectile dysfunction; disorders of libido, orgasm, and ejaculation; Peyronie's disease; and priapism.
Journal ArticleDOI
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan,Faith E. Davies,Walter M Gregory,Kim Cocks,Sue E. Bell,Alex J Szubert,Nuria Navarro-Coy,Mark T. Drayson,Roger G. Owen,Sylvia Feyler,A John Ashcroft,Fiona M. Ross,Jennifer Byrne,Huw Roddie,Claudius Rudin,Gordon Cook,Graham Jackson,J. Anthony Child +17 more
TL;DR: These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.
Journal ArticleDOI
Burkitt's lymphoma
Elizabeth Molyneux,Rosemary Rochford,Beverly E. Griffin,Robert U. Newton,Graham Jackson,Geetha R Menon,Christine J. Harrison,Trijn Israels,Simon Bailey +8 more
TL;DR: Adjuvant monoclonal antibody therapy with rituximab shows promise for improved outcomes and reduced toxic effects in the future.
Journal ArticleDOI
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A Walker,Eileen M Boyle,Christopher P. Wardell,Alex Murison,Dil B Begum,Nasrin M. Dahir,Paula Proszek,David W. Johnson,Martin Kaiser,Lorenzo Melchor,Lauren I. Aronson,Matthew Scales,Charlotte Pawlyn,Fabio Mirabella,John R Jones,Annamaria Brioli,Aneta Mikulasova,David A Cairns,Walter M Gregory,Ana Quartilho,Mark T. Drayson,Nigel H. Russell,Gordon Cook,Graham Jackson,Xavier Leleu,Faith E. Davies,Gareth J. Morgan +26 more
TL;DR: The understanding of genetic events in myeloma is refined and clinically relevant mutations that may be used to better stratify patients at presentation are identified to generate an international staging system mutation score that can identify a high-risk population of patients who experience relapse and die prematurely.
Journal ArticleDOI
The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
Ajay Nehra,Graham Jackson,Martin Miner,Kevin L. Billups,Arthur L. Burnett,Jacques Buvat,Culley C. Carson,Glenn R. Cunningham,Peter Ganz,Irwin Goldstein,André T. Guay,Geoff Hackett,Robert A. Kloner,John B. Kostis,Piero Montorsi,Melinda Ramsey,Raymond C. Rosen,Richard Sadovsky,Richard Sadovsky,Richard Sadovsky,Allen D. Seftel,Ridwan Shabsigh,Ridwan Shabsigh,Ridwan Shabsigh,Charalambos Vlachopoulos,Frederick C. W. Wu +25 more
TL;DR: The Panel's recommendations build on those developed during the first and second Princeton Consensus Conferences, first emphasizing the use of exercise ability and stress testing to ensure that each man's cardiovascular health is consistent with the physical demands of sexual activity before prescribing treatment for ED, and second highlighting the link between ED and CVD, which may be asymptomatic and may benefit from cardiovascular risk reduction.